|
GB9919413D0
(en)
*
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
WO2001032621A1
(en)
*
|
1999-10-29 |
2001-05-10 |
Wakunaga Pharmaceutical Co., Ltd. |
Novel indole derivatives and drugs containing the same as the active ingredient
|
|
AU2002246397B2
(en)
*
|
2001-04-16 |
2005-03-24 |
Tanabe Seiyaku Co., Ltd. |
Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
|
|
KR100901683B1
(ko)
|
2001-08-10 |
2009-06-08 |
닛뽕 케미파 가부시키가이샤 |
퍼옥시좀 증식제 응답성 수용체 δ의 활성화제
|
|
US7119104B2
(en)
|
2001-10-12 |
2006-10-10 |
Nippon Chemiphar, Co., Ltd. |
Activator of peroxisome proliferator-activated receptor delta
|
|
CA2573185A1
(en)
*
|
2004-07-14 |
2006-02-23 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis c
|
|
MX2007004525A
(es)
*
|
2004-10-12 |
2007-09-19 |
Decode Genetics Inc |
Sulfonamidas biciclicas peri-sustituidas para enfermedad de arteria oclusiva.
|
|
WO2006046683A1
(en)
*
|
2004-10-25 |
2006-05-04 |
Astellas Pharma Inc. |
Thiazolylbenzofuran derivatives as leukotriene and prostaglandin d2 receptor antagonists
|
|
GB2431927B
(en)
*
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
|
US8399666B2
(en)
|
2005-11-04 |
2013-03-19 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
|
JP2009526863A
(ja)
*
|
2006-02-15 |
2009-07-23 |
アラーガン、インコーポレイテッド |
スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アンタゴニスト生物学的活性を有するアリールまたはヘテロアリール基を持つインドール−３−カルボン酸アミド、エステル、チオアミドおよびチオールエステル化合物
|
|
CN101460458A
(zh)
*
|
2006-02-15 |
2009-06-17 |
阿勒根公司 |
具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
|
|
CA2649735C
(en)
|
2006-04-18 |
2016-02-09 |
Nippon Chemiphar Co., Ltd. |
Activating agent for peroxisome proliferator activated receptor .delta.
|
|
DE102006021733A1
(de)
*
|
2006-05-09 |
2007-11-22 |
Bayer Healthcare Ag |
3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
|
|
EP2027117A2
(en)
*
|
2006-05-16 |
2009-02-25 |
Decode Genetics EHF |
Process for preparing 7-(acryloyl)-indoles
|
|
DE102006043443A1
(de)
*
|
2006-09-15 |
2008-03-27 |
Bayer Healthcare Ag |
Neue aza-bicyclische Verbindungen und ihre Verwendung
|
|
WO2008089015A1
(en)
|
2007-01-11 |
2008-07-24 |
Allergan, Inc. |
6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
|
|
US8524917B2
(en)
|
2007-01-11 |
2013-09-03 |
Allergan, Inc. |
6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
|
|
AU2009236877B2
(en)
|
2008-04-15 |
2014-01-23 |
Nippon Chemiphar Co., Ltd. |
Activator for peroxisome proliferator-activated receptor
|
|
US8546431B2
(en)
|
2008-10-01 |
2013-10-01 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
NZ724645A
(en)
|
2010-03-12 |
2018-04-27 |
Omeros Corp |
Pde10 inhibitors and related compositions and methods
|
|
CA2822357A1
(en)
|
2010-12-22 |
2012-06-28 |
Abbvie Inc. |
Hepatitis c inhibitors and uses thereof
|
|
CN105102457A
(zh)
|
2013-02-21 |
2015-11-25 |
阿德弗里奥药品有限责任公司 |
{4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
|
|
NZ630803A
(en)
|
2014-04-28 |
2016-03-31 |
Omeros Corp |
Optically active pde10 inhibitor
|
|
NZ630810A
(en)
|
2014-04-28 |
2016-03-31 |
Omeros Corp |
Processes and intermediates for the preparation of a pde10 inhibitor
|
|
EP4006016A3
(en)
*
|
2014-08-29 |
2022-11-16 |
CHDI Foundation, Inc. |
Probes for imaging huntingtin protein
|
|
CA2980801A1
(en)
|
2015-04-24 |
2016-10-27 |
Omeros Corporation |
Pde10 inhibitors and related compositions and methods
|
|
JP2018535969A
(ja)
|
2015-11-04 |
2018-12-06 |
オメロス コーポレーション |
Ｐｄｅ１０阻害剤の固体状態形態
|
|
CN111372576A
(zh)
|
2017-11-17 |
2020-07-03 |
塞尔利克斯生物私人有限公司 |
用于治疗眼部病症的组合物和方法
|